辛伐他汀/ω-3酸乙酯(Simvastatin/Omega-3-Acid Ethyl Esters) - 药物靶点：HMG-CoA reductase x Lipid x Triglyceride_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

HMG-CoA reductase x Lipid x Triglyceride

作用机制

HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)、脂质调节剂、甘油三酯调节剂

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

高脂血症

原研机构

BASF SE

在研机构-

非在研机构

BASF SE

Alfasigma SpA

最高研发阶段终止临床阶段不明

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C25H38O5

InChIKeyRYMZZMVNJRMUDD-HGQWONQESA-N

CAS号79902-63-9

查看全部结构式(2)

关联

3

项与辛伐他汀/ω-3酸乙酯相关的临床试验

EUCTR2007-005582-36-IT / Not yet recruitingN/A

A RANDOMIZED MULTICENTRE PHASE II STUDY TESTING TOLERABILITY AND EFFICACY ON SURROGATE ENDPOINTS (LIPID PROFILE, VASCULAR INFLAMMATORY MARKERS AND THROMBOGENESIS) OF SIMVAPUFA FORMULATION (ASSOCIATION OF SIMVASTATIN AND OMEGA-3 FATTY ACIDS) IN COMPARISON WITH THE ADMINISTRATION OF THE TWO SEPARATE COMPOUNDS, IN PATIENTS WITH ACUTE CORONARY SYNDROME AND POSITIVE BIOCHEMICAL MARKERS OF MYOCARDIAL NECROSIS. - Simva Pufa

开始日期2008-04-07

申办/合作机构

Defiante Farmaceutica Lda.

NCT00487591 / CompletedN/A

An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia

The primary objective of this study is to compare the effect of simvastatin plus Omacor to simvastatin plus placebo for lowering non-high density lipoprotein cholesterol in subjects with mixed dyslipidemia.

开始日期2006-11-01

申办/合作机构

Provident Research, Inc.

[+1]

NCT00903409 / Completed临床3期

OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects

In a previous trial (LOV111858/OM6), subjects received in a double-blind fashion either 4 g/day of Lovaza® (omega-3-ethyl esters) [formerly known as Omacor] co-administered with simvastatin 40 mg/day or placebo co-administered with simvastatin 40 mg/day for 8 weeks. This extension trial, LOV111818/OM6X assessed the continued efficacy and safety of Lovaza® (omega-3-ethyl esters) co-administered with simvastatin 40 mg vs. switching from simvastatin plus placebo to simvastatin plus Lovaza® for lowering non-High Density Lipoprotein-Cholesterol (non-HDL-C) levels at 4 months (primary endpoint) and additionally at 12 and 24 months.

开始日期2005-11-15

申办/合作机构